S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.

Bibliographic Details
Main Authors:	Andreas Hochhaus, Andreas Burchert, Susanne Saußele, Gabriela M Baerlocher, Jiri Mayer, Tim H Brümmendorf, Paul La Rosee, Dominik Heim, Stefan W Krause, Philipp Le Coutre, Christian Fabisch, Jenny Rinke, Thoralf Lange, Alice Fabarius, Marcel Lorch, Mathias Hänel, Frank Stegelmann, Georg-Nikolaus Franke, Markus Radsak, Volker Kunzmann, Danny Himsel, Denise Kohn, Thomas Lang, Rüdiger Hehlmann, Thomas Ernst, Markus Pfirrmann
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000967540.46956.59

Similar Items

Nilotinib-Associated Destructive Thyroiditis
by: Suhalia Bakerywala, et al.
Published: (2015-01-01)

New Biologically Hybrid Pharmacophore Thiazolidinone-Based Indole Derivatives: Synthesis, In Vitro Αlpha-Amylase and Αlpha-Glucosidase Along with Molecular Docking Investigations
by: Shoaib Khan, et al.
Published: (2022-10-01)

One year of experience with nilotinib: the nurse perspective
by: Watts, A, et al.
Published: (2013)

Nilotinib - new step of success in CML therapy
by: E. G. Lomaia, et al.
Published: (2022-11-01)

The case of successful therapy with Nilotinib in patients with Ph-positive chronic myelogenous leukemia of chronic phase resistant to Interferon and Gleevec
by: N. A. Afanasyeva, et al.
Published: (2022-11-01)

Trisomy 21 screening with αlpha software and the Fetal Medicine Foundation algorithm
by: L Pistorius, et al.
Published: (2023-11-01)

PB1972: ASC4START: A PHASE IIIB, OPEN-LABEL, RANDOMIZED STUDY OF ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE
by: Andreas Hochhaus, et al.
Published: (2023-08-01)

Example of successful therapy whith nilotinib at resistant to interferon and glivec patient with chronic phase of Ph-positive chronic myeloid leucosis
by: G. A. Gusarova, et al.
Published: (2008-12-01)

Lapatinib, Nilotinib and Lomitapide Inhibit Haemozoin Formation in Malaria Parasites
by: Ana Carolina C. de Sousa, et al.
Published: (2020-03-01)

Examining the Early Period Effect of Nilotinib on Hearing: An Experimental Study
by: Adem Bora, et al.
Published: (2020-04-01)

S156: INTERNATIONAL, PROSPECTIVE STUDY COMPARING NILOTINIB VERSUS IMATINIB WITH EARLY SWITCH TO NILOTINIB TO OBTAIN SUSTAINED TREATMENT-FREE REMISSION IN PATIENTS WITH WITH CHRONIC MYELOID LEUKEMIA
by: F. Pane, et al.
Published: (2022-06-01)

Alteration of Autophagy and Glial Activity in Nilotinib-Treated Huntington’s Disease Patients
by: Karen E. Anderson, et al.
Published: (2022-12-01)

Machine Learning Approaches to Predict Hepatotoxicity Risk in Patients Receiving Nilotinib
by: Jung-Sun Kim, et al.
Published: (2021-05-01)

Baicalein and Αlpha-Tocopherol Inhibit Toll-like Receptor Pathways in Cisplatin-Induced Nephrotoxicity
by: Amira Awadalla, et al.
Published: (2022-03-01)

Regulation of Αlpha-Synuclein Gene (SNCA) by Epigenetic Modifier TET1 in Parkinson Disease
by: Subhrangshu Guhathakurta, et al.
Published: (2022-11-01)

Concentration of low-density lipoproteins (LDL) is significantly reduced after nilotinib discontinuation
by: Ricardo Roa-Chamorro, et al.
Published: (2023-07-01)

Nilotinib: from animal-based studies to clinical investigation in Alzheimer’s disease patients
by: Annalisa Nobili, et al.
Published: (2023-01-01)

Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
by: Yuji Okamoto, et al.
Published: (2022-10-01)

Nilotinib-induced vasculopathy: Identification of vascular endothelial cells as a primary target site
by: Hadzijusufovic, E, et al.
Published: (2017)

Nilotinib-Associated Multiple Silent Arterial Stenoses in a Patient with Chronic Myeloid Leukemia
by: Mert Tokatlı, et al.
Published: (2024-03-01)

Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia
by: N. A. Avxentyev, et al.
Published: (2018-08-01)

Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model
by: Güldane Seval, et al.
Published: (2017-05-01)

Development of myasthenia gravis in a patient with chronic myeloid leukemia during treatment with nilotinib
by: David Sanford, et al.
Published: (2014-06-01)

Targeting Adaptive IRE1α Signaling and PLK2 in Multiple Myeloma: Possible Anti-Tumor Mechanisms of KIRA8 and Nilotinib
by: Yusuke Yamashita, et al.
Published: (2020-08-01)

A GENOME-WIDE CRISPR/CAS9 SCREENING IDENTIFIES GENETIC MODIFIERS OF ΑLPHA SYNUCLEIN AGGREGATES UPTAKE
by: Benoît Vanderperre, et al.
Published: (2023-10-01)

Remodeling of the liver fibrosis microenvironment based on nilotinib-loaded multicatalytic nanozymes with boosted antifibrogenic activity
by: Huaqing Jing, et al.
Published: (2023-12-01)

FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma
by: Pauline Tétu, et al.
Published: (2020-04-01)

Repurposing the tyrosine kinase inhibitor nilotinib for use against intracellular multidrug-resistant Salmonella Typhimurium
by: Shih-Hsiu Chou, et al.
Published: (2023-06-01)

Nilotinib: A Tyrosine Kinase Inhibitor Mediates Resistance to Intracellular Mycobacterium Via Regulating Autophagy
by: Tariq Hussain, et al.
Published: (2019-05-01)

Chloroquine Intervenes Nephrotoxicity of Nilotinib through Deubiquitinase USP13‐Mediated Stabilization of Bcl‐XL
by: Hao Yan, et al.
Published: (2023-09-01)

The effectiveness of Tocotrienol rich fraction and αlpha Tocoferol with combination of vitamin C in the management of systemic inflammatory response syndrome (SIRS)
by: Husam YE,, et al.
Published: (2017)

PB2532: VARIABLE HEMATOLOGICAL AND CLINICAL PHENOTYPES IN DOUBLE HETEROZYGOTES OF ΒETA-THALASSEMIA AND TRIPLICATED ΑLPHA-GLOBIN GENES
by: Polyxeni Delaporta, et al.
Published: (2023-08-01)

Nilotinib-induced alterations in endothelial cell function recapitulate clinical vascular phenotypes independent of ABL1
by: Emily A. Pinheiro, et al.
Published: (2024-03-01)

Treatment Outcomes of Nilotinib as Second Line Therapy for Chronic Myeloid Leukemia Patients in Karbala Province of Iraq
by: Ahmed Mjali, et al.
Published: (2022-06-01)

Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer
by: Maya Jeitany, et al.
Published: (2018-04-01)

Contribution of intracranial vessel wall magnetic resonance imaging in nilotinib‐associated vascular adverse effects diagnosis
by: Diogo Goulart Corrêa, et al.
Published: (2023-11-01)

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01)

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01)

PB2238: ΒETA-THALASSEMIA INTERMEDIA: INTERACTION OF ΑLPHA-GLOBIN GENE TRIPLICATION WITH ΒETA-THALASSEMIA HETEROZYGOUS IN SPAIN
by: P. Ropero, et al.
Published: (2022-06-01)

Synthesis of Novel Nilotinib Analogues and Biological Evaluation of Their Antiplatelet Activity and Functionality towards Cancer Cell Proliferation In Vitro
by: Louisa Pechlivani, et al.
Published: (2024-03-01)